These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8957034)

  • 1. Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.
    Toto RD; Adams-Huet B; Fenves AZ; Mitchell HC; Mulcahy W; Smith RD
    Am J Kidney Dis; 1996 Dec; 28(6):832-40. PubMed ID: 8957034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years.
    Pedersen EB; Bech JN; Nielsen CB; Kornerup HJ; Hansen HE; Spencer ES; Sølling J; Jensen KT
    Scand J Clin Lab Invest; 1997 Dec; 57(8):673-81. PubMed ID: 9458489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P; Fairley K; Packham D
    Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
    Marre M; Lievre M; Chatellier G; Mann JF; Passa P; Ménard J;
    BMJ; 2004 Feb; 328(7438):495. PubMed ID: 14960504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
    Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.
    Ruggenenti P; Perna A; Remuzzi G
    J Am Soc Nephrol; 2001 Dec; 12(12):2832-2837. PubMed ID: 11729254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].
    Peco-Antić A; Virijević V; Paripović D; Babić D
    Srp Arh Celok Lek; 2004 Oct; 132 Suppl 1():34-8. PubMed ID: 15615462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.
    Hemmelder MH; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1999 Jan; 14(1):98-104. PubMed ID: 10052485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
    Seeman T; Dusek J; Vondrák K; Flögelová H; Geier P; Janda J
    Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension.
    Soergel M; Verho M; Wühl E; Gellermann J; Teichert L; Schärer K
    Pediatr Nephrol; 2000 Nov; 15(1-2):113-8. PubMed ID: 11095026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
    Ruggenenti P; Perna A; Benini R; Remuzzi G
    J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
    Erley CM; Klass M; Krämer D; Berger E; Heyne N; Braun N; Wolf S; Risler T
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):504-9. PubMed ID: 8937934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.
    Iodice C; Balletta MM; Minutolo R; Giannattasio P; Tuccillo S; Bellizzi V; D'Amora M; Rinaldi G; Signoriello G; Conte G; De Nicola L
    Kidney Int; 2003 Jun; 63(6):2214-21. PubMed ID: 12753310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.